J&J drops Addex-partnered epilepsy drug after reviewing failed phase 2 trial data

After mulling over the data from a failed phase 2 trial, Johnson & Johnson has decided to halt development of its Addex Therapeutics-partnered epilepsy drug, Fierce Biotech has learned.

The positive allosteric modulator (PAM) of metabotropic glutamate receptor-2, dubbed ADX71149, emerged from a 2004 collaboration between Addex and J&J’s Janssen unit.